HCC Radioembolization with Yttrium-90 Glass Microspheres (TheraSphere)
Intraarterial radioembolization (RE) using microspheres labelled with the high-energy beta-emitter yttrium-90 (90Y) is an innovative local therapy for hepatocellular carcinoma (HCC). This procedure allows the tumour to be irradiated with a dose higher than that allowed by whole-liver external beam radiation treatment. The TheraSphere (TheraSphere_BTG®) consist of glass microspheres labelled with 90Y as an integral component of glass. The mean diameter of glass sphere is 20–30 μm, and a high specific activity per sphere at calibration is 2500 Bq. The recommended TheraSphere® Dose to the hepatic lobe is 120 Gy (80–150 Gy). It is possible to choose 35 dose size options, between 3 GBq and 20 GBq in 0.5 GBq increments, a dosing flexibility and an individualized patient treatment. Yttrium-90 glass microspheres are indicated for the treatment in early-stage HCC to the downstaging or bridging to liver transplantation or in patients with intermediate to advanced HCC. BCLC B patients refractory to transarterial chemoembolization (TACE) or BCLC C patients with branch portal vein thrombosis (PVT). Considering the favourable tumour response and long-term outcomes, this treatment is an option for unresectable HCC.
KeywordsHCC Radioembolization Dosimetry
- 1.GLOBOCAN. Liver Cancer. Estimated incidence, mortality and prevalence worldwide in 2012. 2012. http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp. Accessed 10 Sept 2015.
- 6.National Comprehensive Cancer Network. NCCN practice guidelines in oncology. Hepatobiliary cancers, V2.2015.Google Scholar
- 13.Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchiano A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C. Yttrium90 radioembolization for intermediate-advanced hepatocarcinoma: a phase II study. Hepatology. 2013;57:1826–37.CrossRefPubMedGoogle Scholar
- 14.Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255–63.CrossRefPubMedGoogle Scholar
- 15.Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging. 2015;42(11):1718–38. https://doi.org/10.1007/s00259-015-3068-8. (Epub 2015 Jun 27)CrossRefPubMedGoogle Scholar
- 16.Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057–68. https://doi.org/10.1007/s00259-013-2395-x.CrossRefPubMedPubMedCentralGoogle Scholar